207 related articles for article (PubMed ID: 32127467)
1. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Histogenesis and Diagnostic Strategy Using Immunoassay and RT-PCR in Alveolar Soft Part Sarcoma.
Ju X; Sun K; Liu R; Li S; Abulajiang G; Zou H; Lan J; Ren Y; Jiang J; Liang W; Pang L; Li F
Pathol Oncol Res; 2018 Jul; 24(3):593-600. PubMed ID: 28766250
[TBL] [Abstract][Full Text] [Related]
8. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
[TBL] [Abstract][Full Text] [Related]
9. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
10. Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.
Lewin J; Davidson S; Anderson ND; Lau BY; Kelly J; Tabori U; Salah S; Butler MO; Aung KL; Shlien A; Dickson BC; Abdul Razak AR
Cancer Immunol Res; 2018 Sep; 6(9):1001-1007. PubMed ID: 30018044
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
[TBL] [Abstract][Full Text] [Related]
14. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
15. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma.
Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Sakamoto A; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2003 Sep; 34(9):841-9. PubMed ID: 14562278
[TBL] [Abstract][Full Text] [Related]
16. Alveolar Soft Part Sarcoma of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases With Emphasis on its Distinction From Morphologic Mimics.
Schoolmeester JK; Carlson J; Keeney GL; Fritchie KJ; Oliva E; Young RH; Nucci MR
Am J Surg Pathol; 2017 May; 41(5):622-632. PubMed ID: 28009610
[TBL] [Abstract][Full Text] [Related]
17. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.
Soheilifar MH; Taheri RA; Zolfaghari Emameh R; Moshtaghian A; Kooshki H; Motie MR
Biomed Pharmacother; 2018 Jul; 103():889-896. PubMed ID: 29710505
[TBL] [Abstract][Full Text] [Related]
18. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
19. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
[TBL] [Abstract][Full Text] [Related]
20. Cediranib for metastatic alveolar soft part sarcoma.
Kummar S; Allen D; Monks A; Polley EC; Hose CD; Ivy SP; Turkbey IB; Lawrence S; Kinders RJ; Choyke P; Simon R; Steinberg SM; Doroshow JH; Helman L
J Clin Oncol; 2013 Jun; 31(18):2296-302. PubMed ID: 23630200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
